Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

This study is testing whether a drug called trilaciclib can reduce bone marrow suppression (low blood cell counts) caused by chemoradiotherapy in people with limited-stage small cell lung cancer. Trilaciclib temporarily protects bone marrow cells from chemotherapy damage. **You may be eligible if...** - You have limited-stage small cell lung cancer (cancer confined to one side of the chest) - Your overall health is adequate for combined chemotherapy and radiation (ECOG 0–2) - Your organ function is in acceptable range **You may NOT be eligible if...** - You have brain metastases that require radiation or steroids - You have an active infection requiring systemic treatment - You are pregnant or breastfeeding - You have certain heart conditions or significant autoimmune diseases Talk to your doctor to see if this trial is right for you.